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Entry of human immunodeficiency virus type 1 (HIV-1) into target cells is mediated by binding of the surface
envelope glycoprotein to the CD4 molecule. Interaction of the resulting CD4-glycoprotein complex with a- or
b-chemokine receptors, depending on the biological phenotype of the virus, then initiates the fusion process.
Here, we show that primary HIV-2 isolates and biological clones, in contrast to those of HIV-1, may use a broad
range of coreceptors, including CCR-1, CCR-3, CCR-5, and CXCR-4. The syncytium-inducing capacity of these
viruses did not correlate with the ability to infect via CXCR-4 or any other coreceptor. One cell-free passage
of the intermediate isolates in mitogen-stimulated, CD81 cell-depleted peripheral blood mononuclear cells
resulted in the outgrowth of variants with CCR-5 only, whereas the coreceptor usage of late and early isolates
did not change. Since HIV-2 is less pathogenic in vivo than HIV-1, these data suggest that HIV pathogenicity
in vivo is not directly related to the spectrum of coreceptors used in in vitro systems.
Human immunodeficiency virus (HIV) entry is mediated by
the binding of its surface glycoprotein to the cellular CD4
molecule, which acts as the primary receptor (7, 18), and the
subsequent interaction of the resulting CD4-envelope glyco-
protein complex with another specific cellular cofactor (26, 28).
Several members of the seven-transmembrane G-protein-cou-
pled receptor family have recently been shown to be possible
coreceptors for HIV-1 or HIV-2 (9, 13, 15, 22, 25). Two mem-
bers of this family, the chemokine receptors CCR-5 and
CXCR-4 (also termed LESTR and fusin), are the main core-
ceptors for macrophage and T-cell line-tropic HIV-1 variants,
respectively (1, 2, 4, 8, 11, 12, 24). A small subset of dualtropic
HIV-1 strains is also able to use other members of this family,
such as the chemokine receptors CCR-2b and CCR-3 (4, 10,
14) or the orphan receptors Bonzo (also termed STRL33) and
BOB (9, 17), as coreceptors. Moreover, longitudinal studies
have shown a shift toward usage of CXCR-4 as coreceptor for
HIV-1 during disease progression, suggesting that the broad-
ening of coreceptor usage contributes to the cytopathic poten-
tial of HIV-1 strains in vivo (6). Compared to HIV-1, HIV-2 is
less transmissible, is less cytopathic in vivo, and induces gen-
erally a slower progression toward AIDS (19). However, we
recently showed that rapid progression can be observed in
some HIV-2-infected individuals (27). Similar to HIV-1, an
inverse correlation was observed between the replication rate
of viruses in vitro and the CD41 T-cell count of the patient
from which they originated (27). Depending on the time re-
quired to detect virus after cocultivation of patient peripheral
blood mononuclear cells (PBMC) with phytohemagglutinin
(PHA)-stimulated PBMC and the CD4 count of the patient,
we were able to distinguish between early (.500 CD4 cells/ml),
intermediate (100 to 500 CD4 cells/ml), and late (,100 CD4
cells/ml) isolates. Studies comparing the requirements for
HIV-1 versus HIV-2 entry may contribute to our understand-
ing of the pathogenicity of these human lentiviruses. Here, we
have evaluated the capacity of a panel of human cells stably
transfected with chemokine receptor genes to support infec-
tion with HIV-2 primary isolates from patients at different
stages of disease (27) (Table 1). Five of the isolates studied
(PH-2-1, RH-2-1, RH-2-2, RH-2-5, and RH-2-7) belong to
HIV-2 subtype A, whereas one isolate, RH-2-6, belongs to
subtype B (27). The megaglioblastoma astrocytic cell line
U87MG, stably transfected with the human CD4 gene and
expression plasmids encoding various coreceptors (15), was
infected with each of these isolates. Cells expressing both CD4
and chemokine receptors were selected regularly with 250 mg
of Geneticin (Gibco BRL) per ml and 1 mg of puromycin
(Calbiochem) per ml, respectively, and CD4 expression of
these cell lines was confirmed by fluorescence-activated cell
sorter analysis (data not shown).
Adherent cells (2 3 104 to 4 3 104) were incubated for 7 to
15 h at 37°C in 24-well plates with a viral inoculum of 250 ml
containing 2,000 cpm of reverse transcriptase (RT) activity.
Cells were then washed once with Dulbecco modified Eagle
medium (DMEM)–10% fetal calf serum (FCS) and cultured in
1.5 ml of DMEM–10% FCS. Virus replication was monitored
at day 10 or 11 postinfection by quantification of RT activity in
150 ml of culture supernatant. The abilities of HIV-2 primary
isolates to infect U87MG CD4 cells expressing different core-
ceptors are shown in Fig. 1.
The early isolate (RH-2-1) used only CCR-5 as its corecep-
tor (Fig. 1A). Intermediate, NSI (non-syncytium-inducing)
isolates (Table 1) PH-2-1, RH-2-5, and RH-2-7 and late, SI
(syncytium-inducing) isolate RH-2-2, all belonging to HIV-2
subtype A, appeared to use a broad range of coreceptors: in
addition to CCR-5, both CCR-1 and CCR-3 were efficiently
used (Fig. 1A). These isolates were also all able to use CXCR-
4, and some entered U87MG CD4 cells via CCR-2b at differ-
ent levels of efficiency. This proved not to be dependent on
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their SI/NSI phenotypes (Fig. 1A). No significant differences in
coreceptor usage were observed between intermediate and late
subtype A isolates (Fig. 1A and Table 1). The late subtype B SI
isolate RH-2-6 (Table 1), however, infected only U87MG CD4
cells expressing the CXCR-4 receptor. In contrast with a pre-
vious study (25), these isolates were unable to infect U87MG
CD4 cells not transfected with any coreceptor. Therefore, the
broad range of coreceptor usage of HIV-2 primary isolates
could not be attributed to their ability to infect U87MG CD4
cells via an unidentified coreceptor constitutively expressed by
these cells.
Virus isolates were passaged with cell-free infection for 1
week in CD8-depleted, PHA-stimulated PBMC. Progeny vi-
ruses were then assayed for coreceptor usage. Replication of
NSI isolates thus passaged was detectable only in CCR-5-ex-
pressing cells, whereas the range of coreceptors used by SI
isolates did not seem to be influenced by this passage (Fig. 1B).
However, prolonged cultivation of NSI isolates in U87MG
CD4 cells for 4 to 7 days after the standard 11 days showed also
a low level of virus production in CCR-1- or CCR-3-expressing
cells (data not shown). This indicated that CCR-1- and CCR-
3-using variants were still present in the isolates after a 1-week
passage in CD8-depleted, PHA-stimulated PBMC. Thus, a
short-term passage in CD8-depleted, PHA-stimulated PBMC
increased preferentially the frequency of CCR-5-restricted
variants present in the NSI isolates.
The selective expansion of a viral subpopulation in CD8-
depleted, PHA-stimulated PBMC suggested that the HIV-2
isolates tested consisted of a pool of variants with different co-
receptor requirements. In order to determine the actual core-
ceptor usage of such HIV-2 variants, we isolated 16 biological
clones from patients PH-2-1, RH-2-5, and RH-2-7 (Table 1).
In short, PBMC from these donors were plated in 96-well
round-bottom plates (Coulter) at 2 3 105, 2 3 104, and 2 3 103
per plate with 4 3 106 PHA-stimulated PBMC from seroneg-
ative individuals per plate. Each well was further treated indi-
vidually, and new medium and cells were added once a week,
according to standard protocols (27). All wells were monitored
after 2 to 3 weeks for the presence of p24 antigen (V5 ELISA;
Organon Technika). p24-positive wells of 96-well plates in
which less than 5 positive wells were detected were considered
clonal. These were further cocultivated with PHA-stimulated
PBMC. Before the assessment of their coreceptor usage, these
clones were passaged for 1 week on CD8-depleted, PHA-
stimulated PBMC. Of the 16 biological clones isolated, two
(PH-2-1 D5 and PH-2-1 H12) exhibited an SI phenotype on
MT-2 cells and/or PHA-stimulated PBMC, whereas the other
14 were NSI variants (Table 1). The two SI biological clones
were obtained from a single individual who progressed rapidly
toward AIDS (within 3 years), suggesting that the fusogenic
potential of the envelope glycoprotein complex contributed to
disease progression in this patient.
All clones were tested for coreceptor usage by infection of
U87MG CD4 cells and appeared to be able to use CCR-5 at
TABLE 1. HIV-2 primary isolates or biological clones
and patient clinical statuses
Patient Clinicalstatusa
CD4
cells/ml
Biological
clone Phenotype Subtype
e
RH-2-1 C1 600 NAb NSI A
PH-2-1 A3 200 NSI A
C1 NSI
C12 NSI
E6 NSI
H8 NSI
D5 SIc
H12 SId
RH-2-7 A3 130 NSI A
A5 NSI
C9 NSI
C12 NSI
D7 NSI
G12 NSI
RH-2-5 A3 110 NSI A
A10 NSI
E4 NSI
E11 NSI
F7 NSI
G7 NSI
RH-2-2 C3 10 NA SId A
RH-2-6 C3 10 NA SId B
a Based on Centers for Disease Control and Prevention criteria.
b NA, not available.
c On PBMC.
d On PBMC and MT-2 cells.
e Based on nucleotide sequences of reverse transcriptase fragments (27).
FIG. 1. Coreceptor usage of HIV-2 primary isolates. Infections were per-
formed with primary isolates cultured for 2 weeks in PHA-stimulated PBMC (A)
and then passaged for 1 week in CD8-depleted, PHA-stimulated PBMC (B).
Each value represents the mean and standard deviation of three independent
experiments and is expressed in counts per minute per 150 ml of supernatant. The
cutoff value was set at two times the mean of all background values. N.T., not
tested.
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very high efficiency (Fig. 2). All but one (PH-2-1 C1) were also
able to use at least one other chemokine receptor as a core-
ceptor. CCR-1, CCR-3, and CXCR-4 were used by 13, 15, and
13 of the 16 clones, respectively. In contrast, CCR-2b was used
by only three clones isolated from a single patient: RH-2-7 C9,
D7, and G12 (Fig. 2B). However, the HIV-2 biological clones
exhibited higher efficiencies of infection via CCR-5 than via the
other coreceptors. This was shown by consistently higher RT
values in CCR-5-expressing cells and detection of virus pro-
duction 2 to 4 days earlier in CCR-5-expressing cells (data not
shown). Finally, no consistent differences in coreceptor usage
between the SI clones PH-2-1 D5 and H12 and the 14 NSI
clones were observed.
It has been stated previously that coreceptor usage of HIV-1
clones is correlated with the viral phenotype: macrophage-
tropic, NSI HIV-1 variants exhibit CCR-5-restricted entry,
whereas SI T-cell line-tropic isolates can also use CXCR-4 (3,
16, 24). The importance of CCR-5-mediated entry has, more-
over, been clearly demonstrated in vivo by the resistance to
HIV-1 infection of individuals who have a homozygous dele-
tion in CCR-5 (20, 21, 23). Our experiments showed that all
but one (RH-2-6) of the HIV-2 biological clones and primary
isolates, of SI or NSI phenotype, can use CCR-5. Therefore, as
described for HIV-1, CCR-5 seems to be the main coreceptor
for primary HIV-2 strains. However, our results do not show a
difference between HIV-2 SI and NSI clones with respect to
their usage of either CXCR-4 or any other coreceptor. Thus, in
contrast to what has been shown for HIV-1 (3, 12, 16), there
seems to be no correlation between any specific coreceptor
usage and HIV-2 syncytium-inducing capacity.
A limited set of HIV-1 strains can use chemokine receptors
other than CCR-5, such as CCR-2b and CCR-3, as their core-
ceptors (4, 10, 14). In contrast to HIV-1, almost all of the
HIV-2 biological clones and primary isolates used in this study
exhibited usage of a broad range of coreceptors, including
CCR-1, CCR-3, and/or CXCR-4 in addition to CCR-5. CCR-1
usage by HIV-1 isolates in vitro has never been documented
and is also consistently absent in our system (13a). Moreover,
14 of the 16 clones tested, including the two SI clones, were
able to use at least three of these chemokine receptors for
entry into U87MG CD4 cells. Therefore, and in contrast with
previous reports (25), broad coreceptor usage seems to be
characteristic of intermediate and late primary HIV-2 variants.
Mitogen-stimulated CD81 T cells have been shown to pro-
duce the natural ligands of CCR-5—RANTES, MIP-1a, and
MIP-1b—which may therefore compete with the HIV enve-
lope glycoprotein for binding to CCR-5 (5, 11). The broad co-
receptor usage of the unpassaged HIV-2 isolates may therefore
have been the result of negative pressure exerted by CD81 T
cells on CCR-5-restricted variants. The preferential selection
of CCR-5-restricted viruses within 1 week of cultivation in CD8-
depleted, PHA-stimulated PBMC implies, however, that CCR-
5-mediated entry is the main mechanism of infection of CD41
cells in vitro by HIV-2 NSI isolates and that other coreceptor
usage may occur when the efficiency of CCR-5-mediated entry
has decreased.
It has been hypothesized that broadening of HIV-1 corecep-
tor usage contributes to the in vivo cytopathogenicity of HIV
by increasing the numbers of potential target cells (6). Despite
the broad coreceptor usage of HIV-2 isolates in vitro, disease
progression in HIV-2-infected individuals is significantly slow-
er than for HIV-1-infected patients (19). Moreover, by using
HIV in situ hybridization and in situ histochemistry of lym-
phoid tissues from early- and intermediate-stage disease pa-
tients, we have recently obtained evidence that the number of
productively infected cells is significantly lower in HIV-2-in-
fected individuals than in HIV-1-infected individuals (26a).
This suggests that the broad coreceptor usage observed in vitro
does not add to the in vivo cytopathogenicity of HIV-2, in
contrast to syncytium-inducing capacity or viral load. There-
fore, additional longitudinal studies are required to further
elucidate the relevance of coreceptor usage in disease progres-
sion after HIV-2 infection.
U87MG CD4 transfected cells were kindly provided by D. Littman.
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